CLINICAL TRIALS PROFILE FOR BEMPEDOIC ACID; EZETIMIBE
✉ Email this page to a colleague
All Clinical Trials for BEMPEDOIC ACID; EZETIMIBE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03001076 ↗ | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) | Completed | Esperion Therapeutics | Phase 3 | 2016-11-29 | The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol. |
| NCT03001076 ↗ | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) | Completed | Esperion Therapeutics, Inc. | Phase 3 | 2016-11-29 | The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol. |
| NCT03051100 ↗ | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C | Completed | Esperion Therapeutics | Phase 2 | 2017-01-19 | The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol. |
| NCT03051100 ↗ | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C | Completed | Esperion Therapeutics, Inc. | Phase 2 | 2017-01-19 | The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol. |
| NCT03337308 ↗ | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy | Completed | Esperion Therapeutics | Phase 3 | 2017-10-23 | The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy. |
| NCT03337308 ↗ | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy | Completed | Esperion Therapeutics, Inc. | Phase 3 | 2017-10-23 | The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BEMPEDOIC ACID; EZETIMIBE
Condition Name
Clinical Trial Locations for BEMPEDOIC ACID; EZETIMIBE
Trials by Country
Clinical Trial Progress for BEMPEDOIC ACID; EZETIMIBE
Clinical Trial Phase
Clinical Trial Sponsors for BEMPEDOIC ACID; EZETIMIBE
Sponsor Name
